We evaluated the pre-clinical efficacy of a novel intraperitoneal (i.p.) sustained-release paclitaxel formulation (PTX ePC ) using bioluminescent imaging (BLI) in the treatment of ovarian cancer. Human ovarian carcinoma cells stably expressing the firefly luciferase gene (SKOV3 Luc ) were injected i.p. into SCID mice. Tumour growth was evaluated during sustained or intermittent courses of i.p. treatment with paclitaxel (PTX). In vitro bioluminescence strongly correlated with cell survival and cytotoxicity. Bioluminescent imaging detected tumours before their macroscopic appearance and strongly correlated with tumour weight and survival. As compared with intermittent therapy with Taxol s , sustained PTX ePC therapy resulted in significant reduction of tumour proliferation, weight and BLI signal intensity, enhanced apoptosis and increased survival times. Our results demonstrate that BLI is a useful tool in the pre-clinical evaluation of therapeutic interventions for ovarian cancer. Moreover, these results provide evidence of enhanced therapeutic efficacy with the sustained PTX ePC implant system, which could potentially translate into successful clinical outcomes.
Ovarian cancer accounts for the majority of deaths from gynaecological malignancies and remains the fifth most common cancer among women (Ozols, 2003) . Ovarian cancer is generally clinically silent, and therefore at the time of diagnosis the majority of patients present with advanced peritoneal metastatic disease (Bookman and Ozols, 1996; Trimble, 2006) . Although a high proportion of patients attain complete clinical remission following initial treatment, unfortunately most relapse. The lack of early detection, metastasis and resistance to chemotherapy make it one of the most difficult malignancies to diagnose and treat, leaving patients with very poor prognosis.
As ovarian cancer is predominantly confined to the peritoneal cavity, strategies such as localised and sustained chemotherapy may have the potential to improve the outcome of chemotherapy. Indeed, several clinical trials have demonstrated survival advantages with localised intraperitoneal (i.p.) chemotherapy and the National Cancer Institute recommends surgery followed by combination of intravenous and i.p. chemotherapy (Ozols et al, 1999; Polyzos et al, 1999; Markman, 2001; Ozols, 2003; Rothenberg et al, 2003; Armstrong et al, 2006; Walker et al, 2006) . Unfortunately, the majority of patients fail to complete i.p. therapy because of catheter-related complications. Therefore more tolerable therapeutic interventions are required and in this context, we developed a novel implantable paclitaxel drug delivery system (PTX ePC ). Our initial studies demonstrated that PTX ePC provided local and controlled release of PTX over several weeks and that it was safer and better tolerated than commercially available PTX formulated in Cremophor EL (Grant et al, 2005; Ho et al, 2005; Vassileva et al, 2007) .
The availability of an intraperitoneal drug delivery system could therefore allow for further exploitation of the benefits of intraperitoneal chemotherapy while also solving the difficulties associated with the catheter system. We therefore, utilised our formulation and bioluminescent imaging (BLI) to determine whether there are therapeutic advantages in providing sustained vs intermittent intraperitoneal chemotherapy in ovarian cancer.
Establishment of a reliable ovarian cancer xenograft model is an important step in the pre-clinical evaluation of potential treatments. However, monitoring the development and progression of peritoneal disease is difficult. Traditional assessments of efficacy are based on measuring total tumour mass, including areas of necrosis and oedema and do not necessarily evaluate the effects of treatment on the number of viable tumour cells without additional processing and evaluation. In this context, animals must be killed at pre-determined end points, increasing the number of animals required and limiting the possibility of ongoing observation of tumour progression within the same animal. Recently BLI has emerged as a real-time non-invasive method to follow tumour progression (Contag et al, 1997; Edinger et al, 2003; Jenkins et al, 2003a, b; Hollingshead et al, 2004; Craft et al, 2005) . Bioluminescent imaging detects only live, metabolically active tumour cells, which is important in the monitoring of a therapeutic response (Jenkins et al, 2003a, b; Hollingshead et al, 2004; Sato et al, 2004) . Although in recent years BLI has been widely utilised, to date there are scarce reports on BLI and ovarian cancer and none in particular on sustained intraperitoneal chemotherapy. We therefore, stably transfected the SKOV3 human ovarian carcinoma cell line with the firefly luciferase gene and utilised BLI to evaluate the effects of sustained and intermittent i.p. Paclitaxel chemotherapy on ovarian tumour response.
MATERIALS AND METHODS

Tumour cell line co-transfection and selection
The SKOV3 human ovarian adenocarcinoma cell line was obtained from the American Type Culture Collection (Rockville, MD, USA). Cells were grown in monolayer cultures in RPMI-1640 medium supplemented with 10% fetal bovine serum and 1% penicillin/ streptomycin (Invitrogen, Burlington, ON, Canada) in a humidified atmosphere of 5% CO 2 . SKOV3 cells were stably co-transfected with the modified firefly luciferase gene plasmid, pGL3 enhancer vector and the pCI-neo mammalian expression vector for neomycin selection (Promega, Madison, WI, USA) with the Fugene-6 transfection kit (Roche, Laval, QC, Canada). Following transfection, cells were cultured in G418 sulfate (800 mg ml À1 ) containing medium for 10 days. Surviving colonies were exposed to 1 mM D-luciferin potassium salt (Promega, Madison, WI, USA) and imaged by IVISt Imaging System (Xenogen, Alameda, CA, USA) for selection of stably co-transfected luciferase/neo clones (SKOV3 Luc ). Following isolation, SKOV3 Luc cells were maintained and propagated in 400 mg ml À1 G418 sulfate-containing medium.
SKOV3
Luc cells were imaged each week to ensure sustained luciferase expression and studies were commenced 2 months post transfection. Furthermore, to evaluate the stable expression of luciferase over time, SKOV3
Luc cells were continuously cultured in G418 sulfate-free media for 3 months and were periodically imaged. Luciferase expression remained stable relative to the initial imaging results.
PTX cytotoxicity in SKOV3
Luc cells
Exponentially growing SKOV3 Luc cells were exposed to various PTX concentrations ranging from 0 to 17 080 nM for 24, 48 and 72 h. Cells were then exposed to D-luciferin potassium salt, 1 mM in phosphate-buffered saline (Promega, Madison, WI, USA) and imaged to determine bioluminescence as described below. Cell viability was determined by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-di.p.henyl tetrazolium bromide] assay as described earlier (Mosmann, 1983; Ho et al, 2005) and the % cell survival was determined as: ((absorbance (l ¼ 560 nm) treated C absorbance (l ¼ 560 nm) untreated ) Â 100). Linear regression analysis was performed to determine whether a good correlation exists between bioluminescent signal ((Bioluminescence treated C Bioluminescence signal untreated ) Â 100) and cell survival in treated SKOV3 Luc cells. Experiments were performed in triplicate.
Bioluminescent imaging
Bioluminescent imaging was performed with the IVISt Imaging System, composed of a high sensitivity cooled charge-coupled camera mounted in a light-tight box (Xenogen, Alameda, CA, USA). The commercially available Living Imaget software (Xenogen, Alameda, CA, USA) was used to collect and analyse images. For in vitro imaging, the bioluminescent signal was obtained over a 60-s integration period. For in vivo imaging, mice were pre-anaesthetised (Ketamine/Xylazine, 100, 10 mg kg À1 respectively) and were administered D-luciferin potassium salt in saline (100 mg kg À1 ) intraperitoneally. Animals were then placed in an air-tight box in the imaging chamber (with heated stage, 371C) at a distance allowing for whole body imaging in a single field of view. Gray-scale images were initially obtained to provide an anatomical reference for the bioluminescent images, which were then acquired over a 5-min integration time. Regions of interest covering the entire peritoneal cavity were selected, including tumours and total photon counts were determined. Bioluminescent images were collected at various time points throughout the duration of the study.
Generation of xenografts
Female SCID mice (4-to 6-week-old, 18 -20 g), obtained from the University Health Network animal colony (Toronto, ON, Canada) were injected intraperitoneally with 1 Â 10 7 SKOV3 Luc cells, suspended in 200 ml of RPMI-1640 medium. Animals were housed under sterile conditions in microisolator cages, fed standard chow diet with water ad libitum and maintained on an automatic 12-h light cycle at 22 -241C. All studies were conducted using sterile techniques and in accordance with the guidelines of the University Health Network Animal Care Committee and the Canadian Animal Care Council.
Treatment groups
Tumour bearing mice received PTX (60 mg kg À1 total dose over 3 weeks) either as intermittent therapy (i.p. bolus injections of 20 mg kg À1 Taxol s on a q7d Â 3 schedule) or sustained therapy (PTX ePC surgically implanted i.p., providing sustained delivery of 20 mg kg À1 per week) and were compared with controls (drug-free ePC implant). Prior to treatment initiation, release from PTX ePC was confirmed both in vitro and in vivo as described earlier (Grant et al, 2005; Ho et al, 2005; Vassileva et al, 2007) . Treatment was initiated 7 days post SKOV3
Luc inoculation, referred to as Day 0; on this date, three mice were killed for visual and microscopic tumour inspection/analysis, and the remainder of the animals (n ¼ 36), were separated into the various groups as described above (n ¼ 12/each group). Mice were imaged every 2 days post SKOV3 Luc tumour inoculation, at treatment initiation, 24-h posttreatment initiation and every 2 -3 days throughout the course of treatment until the termination of the study. Each week (Days 7, 14 and 21), three mice from each group were randomly selected and killed for analysis of tumours and tissues. Owing to rapid disease progression, a maximum 4-week monitoring period was established. Animals were monitored daily for normal activity, abdominal swelling (peritonitis), weight loss, muscle wasting, abdominal distension, and under-conditioning to assess treatment-related toxicities and disease progression. To monitor abdominal distension, we utilised an autoclavable, fabric measuring tape to measure abdominal girth two times weekly, commencing at the day of tumour inoculation. To assess underconditioning and muscle wasting, we used the 'body conditioning scoring' system as described earlier (Ullman-Culleré and Foltz, 1999) . Briefly, this was done by monitoring changes in flesh coverage of bony protuberances. This has been shown to accurately reflect the health decline in mice that have organ enlargement, such as tumour burden growth. End points included: (1) inactivity, hypothermia, or hunched posture; (2) muscle wasting and under-conditioning using body condition scoring; (3) weight loss or gain in excess of 20%; (4) ulceration/infection at tumour site; or (5) excessive distension of the abdomen as assessed by abdominal girth measurements. Animals that reached these pre-determined ethical end points related to tumour burden and body conditionings were killed. Kaplan -Meier survival curves were constructed.
Plasma, tumour and liver drug concentrations were measured by high performance liquid chromatography as described earlier (Vassileva et al, 2007) . As intraperitoneal ovarian xenografts disseminate throughout the peritoneal cavity, all macroscopic (visible) tumour nodules were excised, harvested and weighed, followed by fixation in 4% paraformaldehyde (PFA) solution. Tumour tissues were paraffin embedded, processed and sectioned.
Markers of proliferation (Ki-67) and apoptosis (terminal deoxytransferase-mediated dUTP nick-end labeling and Caspase 3) were examined.
Immunohistochemistry
Paraffin sections were dewaxed in xylene, passaged through graded alcohols and rinsed in distilled water. Sections were immersed in 10 mM citrate buffer, pH 6, at 95 -1001C for 20 min in a microwavable pressure cooker; cooled and rinsed in PBS, then treated with 1% Pepsin (Sigma, Oakville, ON, Canada) in 0.01 N HCl (pH 2.0) for 15 min at 371C. Endogenous peroxidase and biotin activity were blocked using 3% hydrogen peroxide and avidin/biotin blocking kit (Lab Vision, Fremont, CA, USA). For the assessment of proliferation, sections were incubated at room temperature with the Ki-67 monoclonal antibody (Invitrogen, Burlington, ON, Canada), 1/50 dilution for 1 h. For the assessment of apoptosis, sections were incubated with active caspase 3 (casp3) antibody (Chemicon, Temecula, CA, USA), 1/50 dilution overnight, or with biotin-nucleotide cocktail and DNA polymerase 1 (Promega, Madison WI, USA) for 1 h at 371C for in situ terminal deoxytransferase-mediated dUTP nick-end labeling (TUNEL). Colour development was done with freshly prepared NovaRed solution (Vector Laboratories, Burlington, ON, Canada). Sections were counterstained lightly with Mayer's haematoxylin, dehydrated in alcohols, cleared in xylene and mounted in Permount (Fischer, Ottawa, ON, Canada). Nuclei that stained brownish-red were scored as positive and those that stained blue were scored as negative.
Quantification of tumour proliferation and apoptosis
Tumour sections were imaged using a Nikon Coolpix 990 colour camera mounted on a Nikon Eclipse e400 microscope (Japan). At least 10 fields ( Â 400) were randomly selected from each slide. Positively and negatively stained nuclear areas were collected by using Image J analysis software (NIH, Bethesda, MD, USA). Ki-67, Casp3 and TUNEL-labeling indices were determined as the ratio of areas occupied by the positively stained tumour cell nuclei relative to all tumour cell nuclei.
Statistical analysis
Data are expressed as means ± s.e. Data were analysed using oneway ANOVA and the paired Student's t-test of unequal variance for comparison between groups. Regression analysis was performed to establish correlations and the log-rank test for survival analysis. Differences were considered statistically significant at Po0.05.
RESULTS
In vitro evaluation of PTX in SKOV3
PTX inhibited SKOV3
Luc cell survival in a concentration and timedependent manner as evaluated by BLI and MTT. As duration of exposure was increased, cell survival decreased and the IC 50 values were 683 ± 72, 137 ± 29 and 27 ± 12 nM PTX at 24, 48 and 72 h, respectively. The bioluminescent signal (% control) significantly correlated with the MTT assessment of cell viability (Figure 1) . Furthermore, SKOV3 Luc sensitivity to PTX was similar to the parental SKOV3 cell line (data not shown).
In vivo evaluation of sustained and intermittent PTX chemotherapy
The effect of sustained vs intermittent intraperitoneal PTX administration was examined in vivo in the SKOV3 Luc xenograft model of human ovarian cancer in SCID mice. Sustained intraperitoneal PTX delivery with PTX ePC resulted in significant reduction of tumour growth, whereas intermittent therapy with Taxol had no significant effect on tumour reduction as measured by bioluminescent imaging and tumour weight (Figure 2A -C) . Bioluminescence counts strongly correlated with tumour weight ( Figure 2D ). The difference in tumour growth between treatment groups was also reflected by Ki-67 proliferation indices. Sustained PTX administration with PTX ePC significantly reduced the proliferation index of tumours as compared with both control-and Taxol-treated mice. Moreover, intermittent therapy with Taxol resulted in a significant gradual increase in tumour proliferation as compared with control-and PTX ePC -treated animals ( Figures 3A  and 4) . Proliferation indices significantly correlated with tumour weight (r ¼ 0.98, Po0.05) and bioluminescence signal (r ¼ 0.99, Po0.05).
To further characterise tumour response to treatment, we investigated the degree of apoptosis as measured by Caspase 3 and TUNEL. Sustained PTX ePC treatment significantly increased the proportion of apoptotic tumour cells, whereas intermittent Taxol therapy had no effect ( Figures 3B and C and 4) . Moreover, significant decreases in body weight of control-and Taxol-treated animals was observed by day 25 post SKOV3 Luc inoculation, whereas sustained therapy had no deleterious effects (Figure 5 ), suggesting that PTX ePC chemotherapy was more effective and better tolerated.
Effects of PTX chemotherapy on survival
Sustained PTX administration with PTX ePC significantly increased the probability of survival, whereas intermittent Taxol treatment had no significant effects on survival probability (Figure 6 ). The median survival times (post-tumour inoculation) for the control and intermittent (Taxol) group were 21 and 25 days, respectively. In the PTX ePC group, the probability of survival was 89%, however, all animals were killed on day 26, therefore long-term survival rates, could not be determined.
PTX concentration levels
PTX concentration levels were measured in plasma, liver, tumour and ascites each week. In the PTX ePC group, sustained PTX plasma concentrations were seen from days 7 to 21 of treatment. Paclitaxel concentration levels from the PTX ePC -treated group are displayed Table 1 . As samples were collected 1 week following the final dose of Taxol, it was not surprising that PTX levels were below detection limits in all plasma and tissue samples of the intermittent treatment group.
DISCUSSION
Although intraperitoneal tumour models may offer close representation of clinical disease progression, the assessment of therapeutic efficacy has proven to be a difficult and daunting task because of animal-to-animal variability. In this context, we created a stably luciferase-expressing ovarian cancer cell line and developed an intraperitoneal xenograft model that closely mimics metastatic ovarian cancer. We observed strong correlations between the bioluminescent signal with tumour weight and cell viability and thus employed bioluminescent imaging as a tool to investigate the effects of sustained vs intermittent intraperitoneal administration of PTX on ovarian tumour responsiveness. There are a number of BLI studies monitoring tumour response to different treatments (Contag et al, 1997; Jenkins et al, 2003a; McCaffrey et al, 2003; Hollingshead et al, 2004; Peter et al, 2007) ; however, our report is the first to explore the potential of sustained intraperitoneal chemotherapy with real-time progressive observation in a human ovarian cancer model.
Similarly to previous studies with other cell lines (Jenkins et al, 2003a, b; Hollingshead et al, 2004) , SKOV3
Luc cell survival strongly correlated with bioluminescence. For instance, when SKOV3
Luc cells were exposed to PTX for 24, 48 or 72 h, bioluminescence decreased with increasing concentration, which strongly correlated with the decrease in cell survival. Furthermore, we demonstrate that SKOV3
Luc cells grew rapidly in vivo and generated tumours that were detectable by BLI as early as 4 days post inoculation, which is otherwise impossible with traditional Luc inoculation. Intermittent therapy consisted of 20 mg kg À1 on q7d Â 3 schedule (days 7, 14, 21) and sustained therapy consisted of surgical implantation of PTX ePC releasing 20 mg kg À1 per week (n ¼ 9 per group). Non-treated and drug-free ePC implant controls were combined (n ¼ 18). (A) Relative bioluminescence -bioluminescent signal (counts/s) was normalised to treatment initiation date for individual animals (day 7 post SKOV3 Luc inoculation); the number of mice per group changed as the study proceeded, therefore the bioluminescent signal was obtained from n ¼ 39 on day 0 and 7; n ¼ 6 -15 per group on day 14; n ¼ 3 -8 per group on day 21 and n ¼ 4 -5 per group on day 26; (B) Tumour growth curve; n ¼ 3 -6 tumours per group at each time point (obtained from n ¼ 3 -6 mice per group); (C) Representative examples of successive in vivo bioluminescent images of tumour growth in the same animal for each group. Each image was collected for 5 min. The colour scale bar indicates photon count per pixel. There was a significant difference in tumour growth between groups as measured by bioluminescence and tumour weight, Po0.05, ANOVA (*). (D) Regression analysis revealed significant correlation between bioluminescence and tumour weight (r ¼ 0.97, Po0.05). The anatomical location of tumours upon macroscopic examination reflected bioluminescence. animals. This way, animals with similar-sized tumours were randomised into the various treatment groups and were monitored throughout the course of therapy. The luciferase activity in tumours showed excellent correlation to tumour weight and proliferation, thus validating the model with more traditional tumour evaluation methods. Furthermore, the anatomical location of tumours corresponded to the image obtained by BLI. Similarly, studies with other tumour models have also reported correlations between bioluminescence and tumour weight and/or volume (Peter et al, 2007; Wang et al, 2007) , hence supporting the technique as a sensitive and reliable method of efficacy evaluation. Although BLI has emerged as a powerful tool for the monitoring of in vivo disease progression and regression, its use in endogenous tumours is limited as it relies on the expression of a foreign gene and therefore cannot be directly translated into the clinic (Hollingshead et al, 2004) . Furthermore, it is restricted to small research animals or to the superficial tissues of larger animals as signal intensity may be attenuated by scattering (Jenkins et al, 2003a) . Bioluminescent imaging is two-dimensional and unable to obtain in-depth information; however, the development of bioluminescent tomography has overcome these limitations and three-dimensional images are readily generated (Kumar et al, 2007; Zhang et al, 2008) . Bioluminescent imaging can therefore provide an important window into the effect of therapy.
Sustained PTX chemotherapy provided by the PTX ePC implant significantly reduced tumour growth and enhanced therapeutic response and survival rates in comparison to intermittent Taxol administration at equivalent doses. For instance, tumour Body weight changes in response to chemotherapy. Controland Taxol-treated animals encountered significant weight loss by day 25, indicating disease progression. Furthermore, weights in the PTX ePC treatment group significantly differed from control-and Taxol-treated animals, Po0.05, Student's t-test (*). The number of mice per group changed as the study proceeded, therefore body weights were obtained from n ¼ 39 on day 0 and 7; n ¼ 6 -15 per group on day 14; n ¼ 3 -8 per group on day 21 and n ¼ 4 -5 per group on day 26. Data presented as mean ± s.e.
bioluminescence gradually increased by B27 and 11-fold in the tumours of the control-and Taxol-treated mice, respectively, with regard to treatment initiation date. Meanwhile, bioluminescence in the PTX ePC -treated mice did not intensify, indicating that sustained therapy was more effective. Furthermore, PTX ePC treatment decreased tumour mass and proliferation by B96% and B63-fold, respectively, as compared with controls, whereas intermittent therapy resulted in increased tumour growth. Tumour weights and proliferation indices were B29 and B152-fold greater, respectively, in the Taxol group in comparison to PTX ePC . Interestingly, intermittent Taxol administration resulted in a significant gradual increase in proliferative indices in comparison to non-treated controls, suggesting possible tumour repopulation in between treatment cycles. Indeed, it is thought that intermittent chemotherapy may result in increased rates of tumour repopulation during treatment-free intervals, and thus limit efficacy (Kim and Tannock, 2005) . In this context, there is extensive evidence supporting the occurrence of increased tumour repopulation rates during courses of fractionated radiotherapy; implementation of continuous low-dose radiation schedules have resulted in substantial improvements in local tumour control and survival times (Malaise and Tubiana, 1966; Szczepanski and Trott, 1975; Jung et al, 1990) . Similarly, we have recently demonstrated that sustained Taxol chemotherapy resulted in decreased tumour proliferation and diminished tumour repopulation, as compared with intermittent therapy (Edinger et al, 2003) .
In addition to diminished tumour repopulation, this enhanced tumour responsiveness with PTX ePC , may be as a result of both regional and continuous drug exposure. As ovarian tumours are predominantly confined to the peritoneal cavity, intraperitoneal administration allows for high PTX concentrations directly at the tumour site, whereas continuous exposure increases the proportion of apoptotic tumour cells (Dedrick et al, 1978; Rowinsky and Donehower, 1995) . Indeed, in the PTX ePC treatment group, PTX concentrations in ascites and tumours were 42 and 4110-fold greater than in plasma, respectively, and were accompanied by extensive tumour apoptosis. For instance, the degree of apoptosis in tumours obtained from the PTX ePC treatment group was 416 and 12-fold greater than Taxol and control groups, respectively, indicating that sustained therapy was more effective. Improved and more consistent tumour drug penetration have been previously demonstrated with increased exposure time to PTX, both in xenografts and in patient tumours (Kuh et al, 1999) . Additional targeting of vascularised tumours likely occurred through the circulation as clinically relevant and tolerable drug plasma levels were achieved in the PTX ePC -treated group (range of 12 -31 ng ml À1 in all animals). However, much greater concentrations were accomplished in the peritoneal cavity at the tumour site. Therefore, PTX ePC therapy achieved augmented tumour targeting and diminished systemic toxicity. Alternatively, peak plasma and liver concentration levels have been reported to be about 17 mg ml À1 and 60 mg g À1 respectively, following a single i.p. bolus doses of PTX (20 mg kg À1 ); concentrations associated with numerous toxicities (Tamura et al, 1995; Glantz et al, 1996; Maier-Lenz et al, 1997; Kuzuya et al, 2001; Bardelmeijer et al, 2003) . The diminished toxicity and enhanced efficacy with PTX ePC was also reflected by the lack of significant changes in body weight. Indeed, we have previously demonstrated favourable toxicity profiles with PTX ePC and augmented toxicity with Taxol (Vassileva et al, 2007) . Similarly, weight loss may be reflective of efficacy, as physical wasting is an attribute of disease progression with this model. Both control-and Taxol-treated animals encountered significant weight loss by day 25, indicating disease progression and limited efficacy in the case of intermittent Taxol therapy. Therefore, intermittent therapy results in high systemic levels, which are associated with dose-limiting toxicity and a short-lived therapeutic window.
Localised chemotherapy alleviates systemic toxicities and has demonstrated survival advantages in advanced ovarian cancer patients; however, catheter-related complications currently remain a limitation in the clinical application of intraperitoneal chemotherapy. Our drug delivery system may be a solution to the problems encountered with current intraperitoneal chemotherapy administration practices and allow further exploration of localised drug delivery. Moreover, our formulation provides sustainedrelease of PTX, which may further improve efficacy by diminishing the rates of tumour repopulation and by enhancing tumour cell apoptosis. We also demonstrate that bioluminescent imaging enables earlier detection of tumours than traditional methods and that signal intensity correlates with tumour growth. Therefore, bioluminescent imaging is a non-invasive and rapid approach for the monitoring of experimental tumours and should be further utilised in the pre-clinical evaluation of therapeutic interventions for ovarian cancer. The effects of intermittent Taxol and sustained PTX ePC chemotherapy on survival (Kaplan -Meier curve). Taxol therapy did not result in significant survival advantages in comparison to controls (P ¼ 0.17), whereas sustained PTX ePC therapy resulted in significant survival advantages in comparison to control (P ¼ 0.0001) and Taxol-treated (P ¼ 0.0002) animals.
